SCHEMBL22499118

SCHEMBL22499118

COC(=O)c1cc(C#C[Si](C)(C)C)cc2c1cnn2C1CCCCO1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 5/20 0.42
▸ RXRA P19793 1/20 0.41
▸ RXRB P28702 1/20 0.41
▸ RXRG P48443 1/20 0.41
▸ OPRK1 P41145 4/20 0.35
▸ CYP4F2 P78329 2/20 0.35
▸ CYP4A11 Q02928 2/20 0.35
▸ CYP11B2 P19099 1/20 0.34
▸ KDM4E B2RXH2 3/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ POLB P06746 2/20 0.33
▸ HPGD P15428 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ POLQ O75417 1/20 0.33
▸ TP53 P04637 1/20 0.32
▸ CFTR P13569 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22499208 0.82 ATR (0.43) ATRRXRARXRBRXRGOPRK1
SCHEMBL30811680 0.82 ATR (0.43) ATRRXRARXRBRXRGOPRK1
SCHEMBL31178947 0.79 ATR (0.43) ATRRXRARXRBRXRGOPRK1
SCHEMBL22941293 0.78 CYP11B2 (0.48) ATRRXRARXRBRXRGCYP4F2
SCHEMBL22499385 0.78 ATR (0.52) ATRRXRARXRBRXRGCYP4F2
SCHEMBL30811785 0.76 RXRA (0.39) ATRRXRARXRBRXRGCYP4F2
SCHEMBL22499381 0.75 RXRA (0.44) ATRRXRARXRBRXRGCYP4F2
SCHEMBL30959492 0.74 RXRA (0.40) ATRRXRARXRBRXRGOPRK1
SCHEMBL767226 0.74 RXRA (0.55) ATRRXRARXRBRXRGCYP4F2
SCHEMBL21796883 0.73 RXRA (0.49) ATRRXRARXRBRXRGOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-12-25 — — US disclosed
US-12358915-B2 METTL3 inhibitory compounds STORM Therapeutics Ltd. (GB) 2025-07-15 — — US disclosed
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LIMITED (GB) 2023-03-16 — — US disclosed
EP-3946618-A1 METTL3 INHIBITORY COMPOUNDS Storm Therapeutics Ltd (GB) 2022-02-09 — — EP disclosed
CN-113905787-A METTL3 inhibiting compounds 斯托姆治疗有限公司 2022-01-07 — — CN disclosed
WO-2020201773-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2020-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358915-B2 METTL3 inhibitory compounds METTL3, METTL16, DIMT1 ATR 4106/4885RXRA 3680/4885RXRB 3424/4885
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS METTL3, RNMT, TPMT ATR 3179/4885RXRA 3396/4885RXRB 2830/4885
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS METTL3, METTL16, DIMT1 ATR 4106/4885RXRA 3680/4885RXRB 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback